ecancermedicalscience

Research

HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice

18 Jun 2012
M Origoni, P Cristoforoni, S Costa, L Mariani, P Scirpa, A Lorincz, M Sideri

The large amount of literature published over the last two decades on human papillomavirus (HPV)-DNA testing has definitely demonstrated the association between high-risk viral genotypes (hrHPV) and cervical cancer. Moreover, hrHPV-DNA testing has shown excellent performance in several clinical applications, from screening settings to the follow-up of treated patients, compared to conventional cytology or colposcopy options. On the other hand, when a huge number of reports are published on the same subject in a relatively short period of time, with many variations in settings, study designs and applications, the result is often confusion and decreased comprehension by readers. In daily office practice, several different situations (in symptomatic or asymptomatic women) can be positively managed by the correct use of hrHPV-DNA testing. Validated hrHPV-DNA testing and, specifically, the HC2® assay, due to its excellent sensitivity and negative predictive value together with optimal reproducibility, currently represent a powerful tool in the clinician’s hands to optimally manage several situations related to HPV infection and the potential development of cervical cancer.

Article metrics: 3743 views
993
2750

Related Articles

Meetakshi Gupta, Supriya Chopra, Shreya Kunder, A Dheera, Devaraju Sampathirao, Reena Engineer, Jaya Ghosh, Lavanya Gurram, Umesh Mahantshetty, Sudeep Gupta, Shyam Shrivastava
Lucas Minig, José Manuel Bosch, Carmen Illueca, Cristina Zorrero, José Miguel Cárdenas-Rebollo, Julia Cruz, Ignacio Romero
María Eugenia Giavedoni, Lucas Staringer, Rosa Garrido, Cintia Bertoncini, Mabel Sardi, Myriam Perrotta